Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells

Carter, BZ; Mak, PY; Muftuoglu, M; Tao, WJ; Ke, BZ; Pei, JQ; Bedoy, AD; Ostermann, LB; Nishida, Y; Isgandarova, S; Sobieski, M; Nguyen, N; Powell, RT; Martinez-Moczygemba, M; Stephan, C; Basyal, M; Pemmaraju, N; Boettcher, S; Ebert, BL; Shpall, EJ; Wallner, B; Morgan, RA; Karras, GI; Moll, UM; Andreeff, M

Carter, BZ; Andreeff, M (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 448, Sect Mol Hematol & Therapy, 1515 Holcombe Blvd, Houston, TX 77030 USA.

BLOOD, 2023; 142 (12): 1056

Abstract

TP53-mutant acute myeloid leukemia (AML) remains the ultimate therapeutic challenge. Epichaperomes, formed in malignant cells, consist of heat shock p......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索